Sanofi Consumer Healthcare India Limited has submitted to the Exchange, the Outcome of the Board Meeting held today for considering and approval of Audited Financial Results of the Company for the quarter and financial year ended December 31, 2025.
SANOFICONR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 15.6 pts more than Nifty Microcap 250 and 15.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sanofi Consumer Healthcare India reported strong audited results for the year ended December 31, 2025. Revenue from operations rose to ₹8,784 million from ₹7,245 million, a growth of about 21%. Profit after tax jumped to ₹2,401 million from ₹1,810 million, up roughly 33%, with EPS at ₹104.27 versus ₹78.59. For the October–December quarter, revenue grew to ₹2,510 million from ₹1,707 million, driven by 23% domestic growth and a 932% surge in export sales on a low base. The Board has recommended a final dividend of ₹75 per share (face value ₹10), subject to shareholder approval. Statutory auditor Kalyaniwalla & Mistry LLP issued an unmodified opinion, though it included an Emphasis of Matter on related party export transactions with Opella Healthcare International SAS. An exceptional item of ₹66 million (reversal of prior year demerger provision) was also recorded, versus a ₹284 million expense in the previous year.
The strong double-digit revenue and profit growth, coupled with a generous dividend, should be viewed positively by shareholders. The Emphasis of Matter on related party transactions is procedural and does not alter the clean audit opinion, but investors may want to note the governance process around large RPTs with the Opella group.